Crisantaspase

Leukemia

Incyte Corporationprotein_peptidePhase 3Dormant

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 71/ 100
Competitive Position: 65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
Vincristine sulfate Inhye Ahn	Phase 3	BB
Cyclophosphamide National Cancer Institute (NCI)	Phase 4	BB
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3	BB
Daunomycin Richard Stone, MD	Phase 3	BB
THIOGUANINE ANHYDROUS Incyte Corporation	Phase 3	BB

View all 50 →

Same molecule, other indications

Crisantaspase is also rated in:

B-cell acute lymphoblastic leukemiaActive

BB

Indicative · Phase 3

71 / 100

acute lymphoblastic leukemiaActive

BB

Indicative · Phase 4

70 / 100

lymphoblastic lymphomaActive

BB

Indicative · Phase 4

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.